Catalyst Pharmaceuticals(CPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CPRX Catalyst Pharmaceuticals

Trading 12-22 10:02:02 EST

23.99

+0.25

+1.05%

High24.20	Low23.53	Vol76.72K
Open23.74	D1 Closing23.74	Amplitude2.82%
Mkt Cap2.95B	Tradable Cap2.76B	Total Shares122.91M
T/O1.83M	T/O Rate0.07%	Tradable Shares115.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CPRX","market":"US","secType":"STK","nameCN":"Catalyst Pharmaceuticals","latestPrice":23.99,"timestamp":1766415719535,"preClose":23.74,"halted":0,"volume":76718,"delay":0,"floatShares":115016976,"shares":122912387,"eps":1.7084,"marketStatus":"Trading","change":0.25,"latestTime":"12-22 10:02:02 EST","open":23.74,"high":24.1999,"low":23.53,"amount":1832823.553764,"amplitude":0.028218,"askPrice":24.02,"askSize":6,"bidPrice":23.98,"bidSize":188,"shortable":3,"etf":0,"ttmEps":1.7084,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1162962000000,"exchange":"NASDAQ","adjPreClose":23.74,"preHourTrading":{"tag":"盘前","latestPrice":23.74,"preClose":23.74,"latestTime":"09:27 EST","volume":176,"amount":4195.099568,"timestamp":1766413670066},"postHourTrading":{"tag":"盘后","latestPrice":23.74,"preClose":23.74,"latestTime":"19:59 EST","volume":319595,"amount":7587194.71688,"timestamp":1766192383856},"volumeRatio":0.500309,"impliedVol":0.5159,"impliedVolPercentile":0.48},"requestUrl":"/m/hq/s/CPRX","defaultTab":"news","newsList":[{"id":"2591862758","title":"Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2591862758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591862758?lang=en_us&edition=fundamental","pubTime":"2025-12-16 06:22","pubTimestamp":1765837320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  rose 2.37% to $24.18 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index  falling 0.59% to 23,057.41 and Dow Jones Industrial Average  falling 0.09% to 48,416.56.This was the stock's fourth consecutive day of gains.Catalyst Pharmaceuticals Inc. closed 9.03% below its 52-week high of $26.58, which the company achieved on June 9th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Johnson & Johnson  rose 1.22% to $214.17, Pfizer Inc.  rose 2.24% to $26.43, and Abbott Laboratories  rose 2.40% to $128.47.Trading volume  eclipsed its 50-day average volume of 1.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 15, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published indep","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2591564992","title":"Catalyst Pharmaceuticals to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2591564992","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591564992?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:03","pubTimestamp":1765803790,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. President and CEO Rich Daly, along with other members of the management team, will present at the event. The presentation will be available via webcast on the company's website, with a replay accessible for at least 30 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL842S1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","SG9999014039.USD","NDAQ","IE00BGHQF748.EUR","IE00B19Z6F94.USD","BK4588","LU2210150020.SGD","IE00B3QW5Z07.USD","IE0034390439.USD","BK4139","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","SG9999014005.SGD","LU0314104364.USD","CPRX","SG9999014021.USD"],"gpt_icon":0},{"id":"2591246684","title":"Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2591246684","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591246684?lang=en_us&edition=fundamental","pubTime":"2025-12-13 06:23","pubTimestamp":1765578180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  rallied 2.96% to $23.62 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index  falling 1.69% to 23,195.17 and Dow Jones Industrial Average  falling 0.51% to 48,458.05.This was the stock's third consecutive day of gains.Catalyst Pharmaceuticals Inc. closed 11.14% short of its 52-week high of $26.58, which the company achieved on June 9th.The stock outperformed some of its competitors Friday, as Johnson & Johnson  rose 0.75% to $211.58, Pfizer Inc.  rose 0.19% to $25.85, and Abbott Laboratories  rose 1.77% to $125.46.Trading volume  eclipsed its 50-day average volume of 1.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 12, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswir","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2588027319","title":"Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2588027319","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588027319?lang=en_us&edition=fundamental","pubTime":"2025-12-04 06:23","pubTimestamp":1764800580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  rose 2.12% to $23.10 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index  rising 0.17% to 23,454.09 and the Dow Jones Industrial Average  rising 0.86% to 47,882.90.The stock's rise snapped a four-day losing streak.Catalyst Pharmaceuticals Inc. closed 13.09% below its 52-week high of $26.58, which the company reached on June 9th.The stock outperformed some of its competitors Wednesday, as Johnson & Johnson  fell 0.04% to $205.33, Pfizer Inc.  rose 1.67% to $25.57, and Abbott Laboratories  fell 0.82% to $125.29.Trading volume  remained 315,182 below its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 3, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2588706822","title":"Catalyst Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588706822","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588706822?lang=en_us&edition=fundamental","pubTime":"2025-12-02 06:22","pubTimestamp":1764627720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  slid 3.08% to $22.69 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index  falling 0.38% to 23,275.92 and Dow Jones Industrial Average  falling 0.90% to 47,289.33.This was the stock's third consecutive day of losses.Catalyst Pharmaceuticals Inc. closed 14.64% below its 52-week high of $26.58, which the company reached on June 9th.The stock underperformed when compared to some of its competitors Monday, as Johnson & Johnson  fell 0.76% to $205.34, Pfizer Inc.  fell 1.83% to $25.27, and Abbott Laboratories  fell 0.69% to $128.01.Trading volume  remained 227,931 below its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 1, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2585446262","title":"Catalyst Pharmaceuticals to Participate in Bank of America CNS Therapeutics Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585446262","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585446262?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:03","pubTimestamp":1763989390,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals Inc. will participate in the Bank of America CNS Therapeutics Virtual Conference on Monday, December 8, 2025. President and CEO Rich Daly, along with other members of the management team, will represent the company at the event. The presentation is scheduled for 12:35pm ET and will be available via webcast on Catalyst's website, with a replay accessible for at least 30 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5jptKw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU1035773651.USD","LU0170899867.USD","LU1804176565.USD","LU0106831901.USD","IE00BLSP4452.SGD","IE00B1BXHZ80.USD","LU0868494617.USD","BK4553","LU2210149790.SGD","LU0321505439.SGD","IE00B19Z6F94.USD","LU0980610538.SGD","BK4139","IE00B19Z3581.USD","LU0640476718.USD","LU1668664300.SGD","IE0002270589.USD","LU1363072403.SGD","CPRX","LU0320765646.SGD","LU0648001328.SGD","LU1883839398.USD","LU1894683348.USD","NDAQ","LU1791807156.HKD","LU0130517989.USD","LU0314106906.USD","IE00B19Z3B42.SGD","LU1267930227.SGD","LU1496350171.SGD","BK4585","LU0052756011.USD","LU2129689605.HKD","LU2210150020.SGD","LU0130102774.USD","LU1718418525.SGD","LU2095319765.USD","IE00BLSP4239.USD","LU0234572021.USD","LU0417517546.SGD","LU0203347892.USD","BAC","LU0306806265.USD","IE00BGHQF748.EUR","LU0477156797.USD","LU1894683264.USD","LU0098860793.USD","LU1496350502.SGD","BK4504"],"gpt_icon":0},{"id":"2585163976","title":"Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2585163976","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585163976?lang=en_us&edition=fundamental","pubTime":"2025-11-21 06:22","pubTimestamp":1763677320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  rose 1.16% to $22.77 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index  falling 2.15% to 22,078.05 and Dow Jones Industrial Average  falling 0.84% to 45,752.26.Catalyst Pharmaceuticals Inc. closed 14.33% below its 52-week high of $26.58, which the company achieved on June 9th.The stock outperformed some of its competitors Thursday, as Johnson & Johnson  rose 0.28% to $203.07, Pfizer Inc.  fell 1.93% to $24.40, and Abbott Laboratories  fell 1.73% to $123.97.Trading volume  remained 412,031 below its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled November 20, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2584054949","title":"Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™","url":"https://stock-news.laohu8.com/highlight/detail?id=2584054949","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584054949?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:03","pubTimestamp":1763557380,"startTime":"0","endTime":"0","summary":"Attributes 249% Revenue Growth to Portfolio Momentum and Focused ExecutionCORAL GABLES, Fla., Nov.  19, 2025  (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3190892/13009/en/Catalyst-Pharmaceuticals-Recognized-as-One-of-North-America-s-Fastest-Growing-Companies-on-the-2025-Deloitte-Technology-Fast-500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG0V08.USD","BK4588","IE00B19Z6F94.USD","IE00B5TLWC47.USD","CPRX","IE00BYQQ9H92.USD","BK4104","BK4585","FAST","BK4139","IE0034390439.USD","BK4567"],"gpt_icon":0},{"id":"2584937258","title":"Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584937258","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584937258?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:03","pubTimestamp":1763470997,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals Inc. will participate in Citi's 2025 Global Healthcare Conference in Miami on December 2, 2025. President and CEO Rich Daly and other management team members are scheduled to attend. The company has not specified what it will present at the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL2tgnd3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU2456880835.USD","LU1162221912.USD","LU2210149790.SGD","LU0106831901.USD","LU1668664300.SGD","LU2095319765.USD","LU0648001328.SGD","BK4534","LU1244550577.SGD","LU0128525689.USD","BK4112","LU1791807156.HKD","LU0170899867.USD","IE00BGHQF748.EUR","LU2125154778.USD","LU0098860793.USD","BK4588","IE00BSNM7G36.USD","LU1201861249.SGD","LU2462157665.USD","LU0477156953.USD","LU0310800965.SGD","LU1366192091.USD","LU1244550221.USD","BK4559","IE00B64PRP62.GBP","LU0980610538.SGD","LU0130517989.USD","LU2360032135.SGD","LU2236285917.USD","LU1267930227.SGD","LU0162691827.USD","BK4504","NDAQ","LU0320765646.SGD","LU1244550494.USD","IE00BKPKM429.USD","LU0130102774.USD","LU0072461881.USD","BK4139","IE00B3QW5Z07.USD","BK4566","LU2417539215.USD","LU0314104364.USD","BK4585","LU0052756011.USD","BK4207","CPRX","IE00B19Z6F94.USD"],"gpt_icon":0},{"id":"2584677903","title":"Catalyst Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2584677903","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584677903?lang=en_us&edition=fundamental","pubTime":"2025-11-18 06:21","pubTimestamp":1763418060,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  shed 2.67% to $22.56 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index  falling 0.84% to 22,708.07 and Dow Jones Industrial Average  falling 1.18% to 46,590.24.The stock's fall snapped a two-day winning streak.Catalyst Pharmaceuticals Inc. closed 15.12% short of its 52-week high of $26.58, which the company achieved on June 9th.The stock underperformed when compared to some of its competitors Monday, as Johnson & Johnson  rose 1.86% to $199.58, Pfizer Inc.  rose 0.08% to $25.08, and Abbott Laboratories  fell 0.43% to $130.03.Trading volume  remained 308,895 below its 50-day average volume of 1.5 M.Data source: Dow Jones Market Data, FactSet. Data compiled November 17, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independe","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2583682085","title":"Catalyst Pharmaceuticals Chief Compliance/Legal Officer Brian Elsbernd Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682085","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682085?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:02","pubTimestamp":1763157741,"startTime":"0","endTime":"0","summary":"Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL4hDG4k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Catalyst Pharmaceuticals Chief Compliance/Legal Officer Brian Elsbernd Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0034390439.USD","CPRX","IE00B19Z6F94.USD"],"gpt_icon":0},{"id":"2583510703","title":"Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2583510703","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583510703?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:23","pubTimestamp":1763072580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  advanced 1.05% to $23.02 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index  falling 2.29% to 22,870.36 and Dow Jones Industrial Average  falling 1.65% to 47,457.22.Catalyst Pharmaceuticals Inc. closed 13.39% below its 52-week high of $26.58, which the company reached on June 9th.The stock outperformed some of its competitors Thursday, as Johnson & Johnson  rose 0.44% to $195.25, Pfizer Inc.  fell 0.31% to $25.79, and Abbott Laboratories  rose 0.34% to $129.26.Trading volume  remained 224,292 below its 50-day average volume of 1.5 M.Data source: Dow Jones Market Data, FactSet. Data compiled November 13, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2583589606","title":"Catalyst Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2583589606","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583589606?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:21","pubTimestamp":1762986060,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  shed 1.39% to $22.78 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average  rising 0.68% to 48,254.82 and the NASDAQ Composite Index  falling 0.26% to 23,406.46.The stock's fall snapped a three-day winning streak.Catalyst Pharmaceuticals Inc. closed 14.30% short of its 52-week high of $26.58, which the company achieved on June 9th.The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson  rose 0.29% to $194.39, Pfizer Inc.  rose 1.41% to $25.87, and Abbott Laboratories  rose 1.43% to $128.82.Trading volume  remained 188,495 below its 50-day average volume of 1.5 M.Data source: Dow Jones Market Data, FactSet. Data compiled November 12, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is publish","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2582390690","title":"Catalyst Pharmaceuticals Inc. Stock Advances 7.1%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2582390690","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582390690?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:33","pubTimestamp":1762896780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc. rallied 7.1% to $23.10 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 1.2% to 47,927.96 and the NASDAQ Composite Index falling 0.3% to 23,468.30.This was the stock's third consecutive day of gains.Catalyst Pharmaceuticals Inc. closed 13.1% below its 52-week high of $26.58, which the company reached on June 9th.The stock outperformed some of its peers, as Johnson & Johnson rose 2.9% to $193.83, Pfizer Inc. rose 4.6% to $25.51, and Abbott Laboratories rose 0.88% to $127.00.Trading volume totaled 1.4 million, compared to the 50-day average of 1.5 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2582892083","title":"Catalyst Pharmaceuticals (CPRX): Valuation Insights After Strong Q3 Results and New Share Buyback Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2582892083","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582892083?lang=en_us&edition=fundamental","pubTime":"2025-11-09 21:29","pubTimestamp":1762694956,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals (CPRX) shares drew fresh attention after the company reported an impressive third quarter. Revenue and earnings both climbed sharply year over year. Management also raised full-year revenue guidance, reinforcing confidence in future growth.\nSee our latest analysis for Catalyst Pharmaceuticals.\nMomentum has picked up for Catalyst Pharmaceuticals in recent months, with third-quarter earnings, upbeat revenue guidance, and a new $200 million share buyback sparking...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-pharmaceuticals-cprx-valuation-insights-after-stron","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-pharmaceuticals-cprx-valuation-insights-after-stron","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CPRX","IE00B19Z6F94.USD","IE0034390439.USD","BK4139"],"gpt_icon":0},{"id":"2581839725","title":"Catalyst Pharmaceuticals Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2581839725","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581839725?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:03","pubTimestamp":1762549380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 16:03 ET (21:03 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"1138934251","title":"Stock Track | Catalyst Pharmaceuticals Soars 5.10% Pre-Market on Analyst Upgrades and Bullish Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1138934251","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138934251?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:49","pubTimestamp":1762526976,"startTime":"0","endTime":"0","summary":"Catalyst Pharmaceuticals (CPRX) stock is surging 5.10% in pre-market trading on Friday, following a series of positive analyst actions that have bolstered investor confidence in the biopharmaceutical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CPRX"],"gpt_icon":0},{"id":"2581859058","title":"Catalyst Pharmaceuticals price target raised to $33 from $32 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2581859058","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581859058?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:37","pubTimestamp":1762522633,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Leland Gershell raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $33 from $32 and keeps an Outperform ratin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/catalyst-pharmaceuticals-price-target-raised-to-33-from-32-at-oppenheimer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/catalyst-pharmaceuticals-price-target-raised-to-33-from-32-at-oppenheimer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CPRX","OPY"],"gpt_icon":0},{"id":"2581954883","title":"Catalyst Pharmaceuticals, Inc. : Oppenheimer Raises Target Price to $33 From $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2581954883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581954883?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:19","pubTimestamp":1762521540,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nAZN4QLYKT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0034390439.USD","BK4139","IE00B19Z6F94.USD","CPRX"],"gpt_icon":0},{"id":"2581901049","title":"Catalyst Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2581901049","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581901049?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:24","pubTimestamp":1762467840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Catalyst Pharmaceuticals Inc.  slid 1.82% to $20.99 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index  falling 1.90% to 23,053.99 and Dow Jones Industrial Average  falling 0.84% to 46,912.30.Catalyst Pharmaceuticals Inc. closed 21.03% below its 52-week high of $26.58, which the company reached on June 9th.The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson  rose 0.52% to $186.97, Pfizer Inc.  rose 0.98% to $24.85, and Abbott Laboratories  rose 0.33% to $124.95.Trading volume  eclipsed its 50-day average volume of 1.5 M.Data source: Dow Jones Market Data, FactSet. Data compiled November 6, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.catalystpharma.com","stockEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":0.0546},{"period":"3month","weight":0.2002},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1062},{"period":"ytd","weight":0.1375}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.578947,"avgChangeRate":0.055293},{"month":2,"riseRate":0.684211,"avgChangeRate":-0.010782},{"month":3,"riseRate":0.684211,"avgChangeRate":0.101942},{"month":4,"riseRate":0.421053,"avgChangeRate":0.03478},{"month":5,"riseRate":0.578947,"avgChangeRate":-0.029537},{"month":6,"riseRate":0.526316,"avgChangeRate":0.038372},{"month":7,"riseRate":0.578947,"avgChangeRate":0.111528},{"month":8,"riseRate":0.631579,"avgChangeRate":0.2208},{"month":9,"riseRate":0.368421,"avgChangeRate":-0.027783},{"month":10,"riseRate":0.473684,"avgChangeRate":-0.048724},{"month":11,"riseRate":0.578947,"avgChangeRate":0.015249},{"month":12,"riseRate":0.35,"avgChangeRate":-0.029132}],"exchange":"NASDAQ","name":"Catalyst Pharmaceuticals","nameEN":"Catalyst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Catalyst Pharmaceuticals(CPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Catalyst Pharmaceuticals(CPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Catalyst Pharmaceuticals,CPRX,Catalyst Pharmaceuticals股票,Catalyst Pharmaceuticals股票老虎,Catalyst Pharmaceuticals股票老虎国际,Catalyst Pharmaceuticals行情,Catalyst Pharmaceuticals股票行情,Catalyst Pharmaceuticals股价,Catalyst Pharmaceuticals股市,Catalyst Pharmaceuticals股票价格,Catalyst Pharmaceuticals股票交易,Catalyst Pharmaceuticals股票购买,Catalyst Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Catalyst Pharmaceuticals(CPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Catalyst Pharmaceuticals(CPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction